# VASO Corp: overview VASO · OTC · CIK 839087 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vaso.md) · [Financials](/companies/vaso/financials.md) · [Filings](/companies/vaso/filings.md) · [Insiders](/companies/vaso/insiders.md) Latest reported revenue: [$11.2m](/filings/0001213900-26-090009.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001213900-26-090009). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [20.8](/filings/0001213900-25-110955.md) | [27.0 d](/filings/0001213900-26-037664.md) | [19.5](/filings/0001213900-26-057690.md) | [20.0](/filings/0001213900-25-076616.md) | [22.7](/filings/0001213900-25-110955.md) | [27.0 d](/filings/0001213900-26-037664.md) | [19.4](/filings/0001213900-26-057690.md) | [11.2](/filings/0001213900-26-090009.md) | | Gross margin | % | [56.6%](/filings/0001213900-25-110955.md) | [63.7% d](/filings/0001213900-26-037664.md) | [58.4%](/filings/0001213900-26-057690.md) | [39.8%](/filings/0001213900-26-090009.md) | [61.3%](/filings/0001213900-25-110955.md) | [65.2% d](/filings/0001213900-26-037664.md) | [59.8%](/filings/0001213900-26-057690.md) | [79.5%](/filings/0001213900-26-090009.md) | | Operating margin | % | [(6.7%)](/filings/0001213900-25-110955.md) | [8.0% d](/filings/0001213900-26-037664.md) | [(6.3%)](/filings/0001213900-26-057690.md) | [0.5%](/filings/0001213900-26-090009.md) | [6.8%](/filings/0001213900-25-110955.md) | [(10.3%) d](/filings/0001213900-26-037664.md) | [(6.9%)](/filings/0001213900-26-057690.md) | [8.7%](/filings/0001213900-26-090009.md) | | Net margin | % | [(5.7%)](/filings/0001213900-25-110955.md) | [8.0% d](/filings/0001213900-26-037664.md) | [(5.5%)](/filings/0001213900-26-090009.md) | [(1.0%)](/filings/0001213900-26-090009.md) | [7.6%](/filings/0001213900-25-110955.md) | [4.2% d](/filings/0001213900-26-037664.md) | [(4.6%)](/filings/0001213900-26-090009.md) | [4.9%](/filings/0001213900-26-090009.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001213900-25-110955.md) | not reported | [(0.01)](/filings/0001213900-26-057690.md) | [0.00](/filings/0001213900-26-090009.md) | [0.01](/filings/0001213900-25-110955.md) | not reported | [(0.01)](/filings/0001213900-26-057690.md) | [0.00](/filings/0001213900-26-090009.md) | | Free cash flow | $m | not reported | not reported | [(0.9)](/filings/0001213900-26-057690.md) | [6.3 d](/filings/0001213900-26-090009.md) | not reported | not reported | [(13.1)](/filings/0001213900-26-057690.md) | [16.9 d](/filings/0001213900-26-090009.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [75.6](/filings/0001654954-22-004333.md) | [79.3](/filings/0001213900-24-028734.md) | [81.0](/filings/0001213900-25-026337.md) | [86.8](/filings/0001213900-26-037664.md) | [89.1](/filings/0001213900-26-037664.md) | | Gross margin | % | [57.1%](/filings/0001654954-23-004142.md) | [60.4%](/filings/0001213900-24-028734.md) | [62.4%](/filings/0001213900-25-026337.md) | [60.0%](/filings/0001213900-26-037664.md) | [61.4%](/filings/0001213900-26-037664.md) | | Operating margin | % | [3.7%](/filings/0001654954-23-004142.md) | [8.1%](/filings/0001213900-24-028734.md) | [5.2%](/filings/0001213900-25-026337.md) | [0.3%](/filings/0001213900-26-037664.md) | [(3.2%)](/filings/0001213900-26-037664.md) | | Net margin | % | [8.1%](/filings/0001654954-23-004142.md) | [14.2%](/filings/0001213900-24-028734.md) | [5.9%](/filings/0001213900-25-026337.md) | [1.1%](/filings/0001213900-26-037664.md) | [1.8%](/filings/0001213900-26-037664.md) | | Diluted EPS | $ per share | not reported | [0.06](/filings/0001213900-24-028734.md) | [0.03](/filings/0001213900-25-026337.md) | [0.01](/filings/0001213900-26-037664.md) | [0.01](/filings/0001213900-26-037664.md) | | Free cash flow | $m | [7.4](/filings/0001654954-23-004142.md) | [13.9](/filings/0001213900-24-028734.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vaso/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VIMA LLC](/funds/2012155.md) | 2026-06-30 | $38 | 200 | | Not compared | ## Recent filings [All 294 filings](/companies/vaso/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 13:48 ET | [DEF 14A](/filings/0001213900-26-113710.md) | Proxy statement, period 2026-12-08 | 0001213900-26-113710 | | 2026-08-14 | 16:02 ET | [10-Q](/filings/0001213900-26-090009.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090009 | | 2026-08-06 | 16:05 ET | [8-K/A](/filings/0001213900-26-086128.md) | 9.01 Financial statements and exhibits | 0001213900-26-086128 | | 2026-07-31 | 17:01 ET | [8-K](/filings/0001213900-26-084076.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001213900-26-084076 | | 2026-07-23 | 17:14 ET | [8-K](/filings/0001213900-26-080991.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-080991 | | 2026-05-15 | 16:02 ET | [10-Q](/filings/0001213900-26-057690.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057690 | | 2026-05-08 | 16:01 ET | [8-K](/filings/0001213900-26-053854.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-053854 | | 2026-04-16 | 09:03 ET | [SCHEDULE 13D](/filings/0001213900-26-044358.md) | Ownership report, active investor | 0001213900-26-044358 | | 2026-04-10 | 09:29 ET | [SCHEDULE 13D](/filings/0001213900-26-042214.md) | Ownership report, active investor | 0001213900-26-042214 | | 2026-03-31 | 17:25 ET | [10-K](/filings/0001213900-26-037664.md) | Annual report, period 2025-12-31 | 0001213900-26-037664 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037664.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/49bc421a-d7a8-4d08-a2d1-33c424512768) ## About the filer - CIK: 839087 - Tickers: VASO - Exchange: OTC - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 13:52 ET. No prices; not investment advice.